<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: Vaccine Impresario, Todd Patrick, At it Again With Immunization Against Strep Throat</title>
	<atom:link href="http://www.xconomy.com/seattle/2008/11/18/vaccine-impresario-todd-patrick-at-it-again-with-immunization-against-strep-throat/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.xconomy.com/seattle/2008/11/18/vaccine-impresario-todd-patrick-at-it-again-with-immunization-against-strep-throat/</link>
	<description>Business + Technology in the Exponential Economy</description>
	<lastBuildDate>Sat, 21 Nov 2009 22:30:41 -0600</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.6</generator>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
		<item>
		<title>By: David Miller</title>
		<link>http://www.xconomy.com/seattle/2008/11/18/vaccine-impresario-todd-patrick-at-it-again-with-immunization-against-strep-throat/comment-page-1/#comment-40448</link>
		<dc:creator>David Miller</dc:creator>
		<pubDate>Tue, 18 Nov 2008 17:30:52 +0000</pubDate>
		<guid isPermaLink="false">http://www.xconomy.com/?p=6299#comment-40448</guid>
		<description>Our firm covered Todd and Tony&#039;s ID Biomedical from way back. I got to know them pretty well, especially Todd. I joke with Todd all the time that he left money on the table getting &quot;only&quot; $1.5B for ID, but there is no getting around the fact he did really well for shareholders.

We see a lot of schlock out there among biotech companies on the public exchanges. Between pharma cherry picking private companies and no IPO flow, the pickings are pretty slim. We&#039;d be really happy if Todd decided to take this venture public, and I expect we wouldn&#039;t be the only ones -- even in this market.</description>
		<content:encoded><![CDATA[<p>Our firm covered Todd and Tony&#8217;s ID Biomedical from way back. I got to know them pretty well, especially Todd. I joke with Todd all the time that he left money on the table getting &#8220;only&#8221; $1.5B for ID, but there is no getting around the fact he did really well for shareholders.</p>
<p>We see a lot of schlock out there among biotech companies on the public exchanges. Between pharma cherry picking private companies and no IPO flow, the pickings are pretty slim. We&#8217;d be really happy if Todd decided to take this venture public, and I expect we wouldn&#8217;t be the only ones &#8212; even in this market.</p>
]]></content:encoded>
	</item>
</channel>
</rss>
